DHX9 and cancer: Remarkably, the deletion of DHX9 leads to a substantial reduction in cancer cell viability in vitro and fosters a significant boost in immunogenicity in mouse models of small-cell lung cancer, thereby greatly enhancing the responsiveness to immunotherapy 8.